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Mucositis, characterized by ulcerative lesions along the alimentary tract, is a common 
consequence of many chemotherapy regimens. Chemotherapy negatively disrupts the intestinal 
microbiota, resulting in increased numbers of potentially pathogenic bacteria, such as Clostridia 
and Enterobacteriaceae, and decreased numbers of “beneficial” bacteria, such as Lactobacilli and 
Bifidobacteria. Agents capable of restoring homeostasis in the bowel microbiota could therefore 
be applicable to mucositis. Prebiotics are indigestible compounds, commonly oligosaccharides, 
which seek to reverse chemotherapy-induced intestinal dysbiosis through selective colonization 
of the intestinal microbiota by probiotic bacteria. In addition, evidence is emerging that certain 
prebiotics contribute to nutrient digestibility and absorption, modulate intestinal barrier function 
through effects on mucin expression, and also modify mucosal immune responses, possibly via 
inflammasome-mediated processes. This review examines the known mechanisms of prebiotic 















































The treatment of cancer by chemotherapy, sometimes in combination with radiotherapy, is 
associated with an array of acute side-effects, including alopecia, neutropenia and nausea (Logan 
et al., 2007). Furthermore, these treatments can also induce inflammation and deterioration of the 
mucosal membranes of the alimentary tract, a condition referred to as mucositis. Mucositis can 
occur throughout the entire gastrointestinal tract (Gibson et al., 2005); however, it most 
commonly affects the mucosa of the mouth (oral mucositis) and small intestine (gastrointestinal 
mucositis), with symptoms including pain, vomiting, bloating, and diarrhoea. Severe cases are 
often associated with secondary complications such as malnutrition and septicaemia, resulting in 
poor patient outcomes. Indeed, the pathobiology of mucositis is influenced by the nature of the 
causative agent (Logan et al., 2009), with temporal variations in pathogenesis, in addition to the 
location and severity of damage (Logan et al., 2009). Consequently, the multi-factorial nature of 
mucositis makes it a difficult condition to understand, and subsequently treat. 
 
Despite mucositis being one of the most common side-effects of cancer treatment (Choi et al., 
2007) its incidence and severity is highly variable, and is dependent on the treatment regimen 
and individual variation in terms of tolerability (Lalla et al., 2006). Approximately 40% of all 
patients undergoing chemotherapy develop mucositis (Gibson et al., 2002; Lalla et al., 2006) 
with this number rising to between 60% and 100% in patients receiving high-dose chemotherapy 








































To date, effective treatments for intestinal mucositis have been elusive. Potential treatment 
options are limited by the requirement for treatments to protect the mucosa and promote the 
repair process, without compromising cytotoxic effects on the neoplasm. Certain growth factors 
such as epidermal growth factor, transforming growth factor-α and betacellulin (Choi et al., 
2008; Dahlhoff et al., 2008; Sukhotnik et al., 2008a; Sukhotnik et al., 2008b; Boukhettala et al., 
2010; Kim et al., 2010) have the potential to promote differentiation and proliferation of 
epithelial cells, and ‘prime’ the intestine prior to chemotherapy, in addition to accelerating the 
repair process. Previously, keratinocyte growth factor-1 (KGF-1) has shown efficacy in the oral 
form of the condition (Blijlevens and Sonis, 2007), and decreased diarrhoea in a rat model of 
irinotecan-induced mucositis (Gibson et al., 2005), however, it is yet to be applied extensively in 
the treatment of intestinal mucositis in humans. Other growth factors, such as whey growth 
factor extract (WGFE) (Howarth et al., 1996; Clarke et al., 2002; Tran et al., 2003), insulin-like 
growth factor-I (IGF-I) (Howarth et al., 1998; Howarth, 2003; Cool et al., 2005) and fibroblast 
growth factor-20 (FGF-20) (Gibson et al., 2007) have also been investigated, demonstrating 
variable efficacy. Although in their infancy, nutraceutical agents have recently been tested in 
experimental models for efficacy against mucositis. These include plant extracts such as grape 
seed extract (Cheah et al., 2009) and Iberogast (Wright et al., 2009), and animal-sourced oils 
such as Lyprinol (Torres et al., 2008) and Emu Oil (Lindsay et al., 2010). 
 
Development of Mucositis 
Mechanisms underlying the development of mucositis are complex, and still not fully 






































initiation of mucositis occurs directly after chemotherapy administration and is characterised by 
the production of reactive oxygen species (ROS) (Sonis et al., 2004; Lalla and Peterson, 2006; 
Logan et al., 2007). These then activate nuclear factor-κB, (NF-κB) (Logan et al., 2009), a 
transcription factor implicated in promotion of the inflammatory response in conditions 
including arthritis and the inflammatory bowel diseases (Mankan et al., 2009). NF-κB is thought 
to be directly responsible for the up-regulation of pro-inflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6 (Logan et al., 2009). These cytokines 
further amplify damage to the mucosal cells (Sonis et al., 2004). Mucositis first becomes 
clinically evident during the fourth phase, termed ‘ulceration and inflammation’ (Sonis, 2004a). 
It is during this stage that the epithelial layer increases in permeability, allowing the translocation 
of bacteria into the blood stream. This is accompanied by severe pain and discomfort, and 
sometimes secondary complications such as malnutrition and septicaemia (Logan et al., 2007). 
Further changes occur during the ulcerative stage, including crypt ablation and villus atrophy, 
leading to a decrease in the overall absorptive area of the intestine, a decrease in digestive 
enzymes, and an increase in intestinal permeability, with subsequent increases in bacterial 
translocation and alterations in the gut microbiota (Stringer et al., 2009b). Following the 
discontinuation of chemotherapy or radiotherapy, symptoms resolve and mucosal repair begins, 
characterised by proliferation and differentiation of tissues and cells (Sonis et al., 2004; Lalla and 
Peterson, 2006). Currently, our understanding of the mechanisms underlying these changes is 
incomplete, and a role for apoptosis as an early event has been proposed (Sonis, 2004b). Through 






































mucositis, and the mechanisms by which these interactions can be influenced, it is possible that 
the local microbiota could be altered in such a way as to lessen the severity of the condition. 
 
The Bowel Microbiota and Development of Intestinal Mucositis 
The role of the gut microbiota in the development of intestinal mucositis awaits clear 
definition; although evidence is emerging that the symbiotic relationship between the microbiota 
and its host is negatively disrupted by chemotherapy (Stringer et al., 2009a; Stringer et al., 
2009b). This may have important implications for both the severity of mucositis, and the overall 
health of the host. The microbiota may influence the development and severity of mucositis 
through at least five different mechanisms. These include influencing the inflammatory response, 
intestinal permeability, the composition of the mucin layer, epithelial repair, resistance to 
harmful stimuli, and the gut immune system (van Vliet et al., 2010). In mucositis, there is a shift 
in composition of the microbiota away from commensals and ‘beneficial’ bacterial species, such 
as Bifidobacteria spp. and Lactobacillus spp., towards more ‘pathogenic’ microbes such as 
Clostridia and Enterobacteriaceae (Stringer et al., 2009a). Recent studies have also demonstrated 
decreases in goblet cell numbers and mucin secretion associated with chemotherapy 
administration (Stringer et al., 2009b). Maintaining a healthy microbiota and mucin layer during 
chemotherapy treatment could minimise the likelihood of bacterial translocation and secondary 
infection arising from mucositis. Probiotic microorganisms hold potential in this context. 
Probiotics are defined as living microorganisms which when administered in adequate amounts, 
exert desirable health benefits on the host (Reid, 2005). A recent review by Prisciandaro et al. 






































Enterococcus and Streptococcus species may reduce the severity of chemotherapy-induced 
mucositis. Modalities capable of stimulating colonisation of the bowel by probiotic bacteria more 
globally could be a potential strategy to restore intestinal homeostasis. Prebiotics could represent 
such a strategy. 
 
PREBIOTICS 
The concept of prebiotics, and targeted modulation of the gut microbiota was introduced in 
1994-1995 (Delzenne and Roberfroid, 1994; Gibson and Roberfroid, 1995), with the definition 
of prebiotics as compounds that ‘selectively stimulate the growth and/or activity of microbial 
species in the gut microbiota and confer health benefits to the host’ (Roberfroid et al., 2010). In 
order to be classified as a prebiotic, a given substance must be neither hydrolysed nor absorbed 
in the proximal gastrointestinal tract, must be selectively fermented by one or a limited number 
of beneficial bacteria in the intestine and be able to alter the colonic microbiota toward a 
healthier composition (Gibson and Roberfroid, 1995; Looijer-van Langen and Dieleman, 2009; 
Roberfroid, 2007). The fermentation of prebiotics in the colon produces short-chain fatty acids 
(SCFA), which support proliferation of the colonic microbiota (Yanahira et al., 1995), 




A wide variety of compounds have the potential to meet the requirements for definition as a 
prebiotic, although at this stage, not all have been studied sufficiently to classify them as such. 






































2005), a plant derived fructan, lactulose (Bovee-Oudenhoven et al., 2003), galacto-
oligosaccharide (GOS) (Shoaf et al., 2006; Alliet et al., 2007), derived from milk and fructo-
oligosaccharide (FOS) (Cherbut et al., 2003), also having plant origins. Other compounds studied 
for their prebiotic potential include mannan-oligosaccharides (MOS) (Yang et al., 2008b), β-1,4-
mannobiose (MNB) (Ibuki et al., 2010), sialyl-oligosaccharides (SOS) (Sinclair et al., 2008), 
xylo-oligosaccharides (XOS) (Xu et al., 2009), germinated barley foodstuff (GBF) (Kanauchi et 
al., 2008), epilactose (Nishimukai et al., 2008; Watanabe et al., 2008), arabinoxylan-
oligosaccharides (AXOS) (Maki et al., 2012) and chito-oligosaccharides (COS) (Liu et al., 
2008). 
 
Different prebiotics may exert an array of biological effects, including alteration of gut 
morphology (Leforestier et al., 2009), stimulation of mucosal and systemic immune responses 
(Eiwegger et al., 2010; Gopalakrishnan et al., 2012), alteration of local gut microbial 
communities, such as by enhancing the proliferation of probiotics (Lactobacillus plantarum L12 
and Bifidobacterium pseudocatenulatum B7003) in vitro (Marotti et al., 2012), modulation of 
inflammation (Pilzner et al., 2012), changes in mucin production (Leforestier et al., 2009) and a 
decreased occurrence of infection in the first six months of life (Arslanoglu et al., 2007). 
Prebiotics have also been reported to alter the uptake of various nutrients and minerals, such as 
calcium, from the intestine (Abrams et al., 2005; Bakker-Zierikzee et al., 2005). Considered 








































Prebiotics and Intestinal Dysfunction 
One of the earliest studies to investigate the influence of indigestible carbohydrates on gut 
dysfunction examined the effect of FOS ingestion in immunoglobulin A (IgA) deficient dogs 
with small bowel bacterial overgrowth (Willard et al., 1994). This study concluded that FOS 
ingestion altered the microbial communities in the small intestine towards fewer 
aerobic/facultative anaerobic species, although the exact mechanism and implications of these 
findings were not determined. The following year, Gibson and Roberfroid (1995) introduced the 
concept of a ‘prebiotic’ as it is defined today, and in later studies, introduced two other major 
postulates. Firstly, the concept of targeted modulation of the intestinal microbiota (Gibson, 1998) 
and secondly, the use of prebiotics and probiotics concurrently, which has come to be known as 
‘synbiotics’ (Roberfroid, 1998). 
 
This early work, and the establishment of set criteria for a ‘prebiotic’ resulted in a number of 
studies examining the effect of oligosaccharides on the microbiota (Yanahira et al., 1995) and 
digestibility studies on substances suspected of containing indigestible oligosaccharides (Brand-
Miller et al., 1998). Recently, Bogusławska-Tryk et al. (2012) reported that inulin and FOS type 
fructans increased probiotic bacteria, while decreasing certain pathogens. Additionally, these 
investigators reported that inulin and FOS increased the length of the small and large intestines 
in chickens and this contributed to an increase in intestinal enzymatic activity, which in turn led 







































De Souza Oliveira et al. (2012) suggested that one of the beneficial effects of the prebiotic 
inulin, during the fermentation process of skim milk by Streptococcus thermophilus and 
Lactobacillus rhamnosus, was due to the release of fructose, which could act as a carbon and 
energy source for the host. In the setting of clinical cancer treatment, this carbon and energy 
source could potentially be used to enhance the energy levels available to chemotherapy patients 
struggling with nutrient malabsorption due to mucositis. 
 
These studies were followed by investigations into disease states characterised by an 
imbalance in the commensal microbiota, particularly in the colon. Certain prebiotics have 
revealed therapeutic promise in the treatment of inflammatory bowel disease (Kumar et al., 
2012) and researchers are now investigating prebiotics for their potential to treat other gut 
disorders which include acute infantile diarrhoea (Agustina et al., 2007) and irritable bowel 
syndrome (Fedorak and Madsen, 2004). As mucositis is characterised by a disrupted intestinal 
microbiota it could be clinically rewarding to test the capacity for prebiotics to normalize the 
composition of the gut flora.  
 
Prebiotics and Cancer  
Some studies have indicated that prebiotics such as FOS may play an important role in cancer 
prevention (Daddaoua et al., 2007; Sung and Choi, 2008). Clark et al. (2012) recently reviewed 
the effect of prebiotics on biomarkers of colorectal cancer (CRC) and concluded that certain 
prebiotics had the potential to prevent colonic cancer. In their review, potential biomarkers of 






































neoplasia occurrence, cell proliferation, gene expression, and DNA methylation, which were 
likely more indicative relating to CRC risk (Clark et al., 2012). Furthermore, it has been 
suggested that secondary markers, such as toxic compounds in the colon or rectum, protein 
degradation, and bacterial enzyme activity could also be considered in CRC prevention (Clark et 
al., 2012). Indeed, recurrence rate of adenomatous polyps was decreased after administration of 
non-digestible lactulose in humans (Roncucci et al., 1993; Clark et al., 2012). These endpoints 
could be used in the future study of prebiotics on mucositis. It has become evident that prebiotic-
type compounds present in milk, such as GOS, play an important role in the development of the 
neonatal gut, and immune system (Fanaro et al., 2005; Arslanoglu et al., 2007). Modulating 
cancer-related biomarkers of proliferation, apoptosis and immune modulation via prebiotic 
administration could be equally applied in mucositis pathogenesis, although we await 
appropriately controlled studies in this context.  
 
Prebiotics and the Microbiota 
The mucosal barrier on the epithelial surface of the intestine consists, in part, of colonized 
bacterial communities, which may contribute to the defensive gut barrier and guard against other 
pathogen colonization and subsequently decrease the likelihood of bacterial translocation (Gori 
et al., 2011). However, chemotherapy administration can induce changes in bacterial 
communities to a more pathogenic composition (Stringer et al., 2009b). Microbiota composition 
in the small and large intestine were significantly altered by 5-FU injection in rats. Specifically, 






































Escherichia spp. increased in the jejunum, whereas, levels of Enterococcus spp., Lactobacillus 
spp. and Streptococcus spp. were decreased in the colon. 
 
The ability for prebiotics to alter the commensal microbiota towards a beneficial composition 
has been demonstrated in several studies. For example, a prebiotic oligosaccharide mixture 
administered to humans improved gut microbiota composition, as measured by an increase in 
Bifidobacteria and a reduction in the levels of pathogenic Clostridia-related species (Gori et al., 
2011). In broiler chickens, MOS and FOS affected the microbiota composition of the small 
intestine. Yang et al. (2008a) reported that MOS ingestion decreased mucosa-associated 
Coliform spp. in the jejunum in an Escherichia coli challenge model in broiler chickens (Yang et 
al., 2008a), and the same authors also demonstrated that FOS increased Lactobacillus spp. levels 
in the jejunum, and lactic acid levels in the ileum in both the Escherichia coli challenged and 
non-challenged model. Several other studies have shown similar results, with an increase in 
Bifidobacteria spp. and Lactobacillus spp. in both rat large intestine and human fecal material 
following administration of FOS (Lara-Villoslada et al., 2006; Ten Bruggencate et al., 2006). 
Moreover, when FOS was administered in conjunction with L. paracasei to gnotobiotic piglets, 
the increase in Bifidobacteria spp. and Lactobacillus spp. was prolonged and enhanced, 
compared to piglets administered the probiotic alone (Bomba et al., 2002). AXOS has also been 
reported to alter lactic acid bacteria and Clostridium sp. composition in sturgeon fish species 
(Geraylou et al., 2012). Recently, it has been reported that the administration of a specific 
prebiotic mixture (short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides, 






































lactobacilli than the placebo group (Salvini et al., 2011). Together, these studies demonstrated 
that prebiotics have the potential to consolidate the beneficial bacterial composition of the 
mucosal barrier in the small and large intestine as well as altering the profile of the microbiota in 
fecal material.  
 
The altered microbiota may in turn compete with pathogenic bacteria for adhesion sites in the 
gut. However, evidence is still lacking to confirm the capacity for prebiotics to normalise the 
composition of the microbiota in specific areas of the small and large intestine in mucositis. In 
addition, prebiotics are able to decrease gut pH and modulate the SCFA pattern, resulting in an 
inhospitable environment for pathogens (Eiwegger et al., 2010; Gori et al., 2011). Collectively, 
the stimulation of favourable strains of bacteria in the gut, and a reduction in gut pH, may also 
contribute to enhanced immune defences in the mucosal barrier. This could represent a fertile 
area for future research.  
 
Nevertheless, not all prebiotic studies have resulted in clinical improvements. For example, 
the prebiotic, MOS, failed to improve growth performance in pigeons, nor improve the immune 
response against the Newcastle disease virus (Khan et al., 2012). This indicates that our 
understanding of the potential applications for prebiotics is limited and suggests that a range of 
factors, particularly the amount and type of prebiotic supplement used, the species and health 







































Further evidence is emerging that administration of prebiotics can alter gene expression in the 
gut through their fermentation products, in particular, butyrate (Sauer et al., 2007; Rodenburg et 
al., 2008). Butyrate has been identified as a potential anti-neoplastic agent in the colon (Scharlau 
et al., 2009), has been shown to induce apoptosis in gastric cancer cells (Matthews et al., 2007) 
and also plays an essential role in the regeneration of the mucosa (Sauer et al., 2007) and in 
inhibition of pro-inflammatory cytokine production in rat mesenteric lymph nodes (Looijer-van 
Langen and Dieleman, 2009). 
 
Prebiotics and Mucins 
The mucin layer is an integral component of barrier function in the intestine (Stringer et al., 
2009b). Mucins form gels and generate a protective mucus blanket overlying the epithelial 
surface protecting the mucosa from bacterial overgrowth and/or penetration (Specian and Oliver, 
1991). Mucins also produce a physical and chemical barrier that protects the epithelium from 
luminal agents such as enteric bacterial toxins (Specian and Oliver, 1991). In addition, mucins 
create an enormous repertoire of potential binding sites for microorganisms, such as commensal 
and pathogenic bacteria (Robbe et al., 2004). 
 
It has been proposed that inhibition of bacterial adhesion occurs as a result of terminal sugars 
on prebiotics interfering with receptors on the bacteria that facilitate adhesion to the intestinal 
mucin layer (Forchielli and Walker, 2005). Sinclair et al. (2008) demonstrated that this 
interference was not unique to bacterial cells, with a study using sialyloligosaccharide shown to 






































increased mucin production (Ten Bruggencate et al., 2006; Leforestier et al., 2009) resulting in 
reduced bacterial translocation and consequently, a lower incidence of pathogenic infection 
(Looijer-van Langen and Dieleman, 2009). In contrast, chemotherapy agents significantly 
decreased epithelial mucin levels in the jejunum in rats treated with 5-FU (Stringer et al., 2009b) 
although, mucus secretion in the large intestine was increased in irinotecan treated rats (Gibson 
et al., 2003). Therefore, it is clear that chemotherapy can induce mucin changes in rats. However, 
there is still insufficient evidence to definitively predict mucin changes induced by different 
chemotherapy agents.  
 
Prebiotics, on the other hand, could have the ability to prevent chemotherapy-induced damage 
to the gut by maintaining mucosal integrity through mucin modification. However, the capacity 
for prebiotics to alter mucin levels in the different intestinal regions in the mucositis setting 
requires future research. 
 
Prebiotics and the Gut Immune System 
The gut mucosal lining contains organized lymphoid tissues that support the initiation of anti-
microbial immune responses (Rancez et al., 2012). Lymphoid cells can be orchestrated by 
chemokines, trafficking and positioning into different mucosa-associated lymphoid tissues, 
contributing to immune defence (Rancez et al., 2012). Prebiotics therefore have the potential to 
modulate lymphoid cells and stimulate the gut immune system (Forchielli and Walker, 2005; 
Daddaoua et al., 2007; Geraylou et al., 2012). For example, administration of FOS directly 






































production (Looijer-van Langen and Dieleman, 2009; Yasuda et al., 2012). IgA is the dominant 
antibody associated with mucosal immunity, and plays an important role in inhibition of 
pathogen adhesion to the intestinal wall and the activation of macrophages (Looijer-van Langen 
and Dieleman, 2009). Recently, Yasuda et al. (2012) reported that FOS decreased allergic 
peritoneal inflammation in mice through increased local synthesis of IgA. However, prebiotics 
such as FOS and inulin did not affect IgA levels in dogs (Patra, 2011) or in humans treated with 
AXOS (Walton et al., 2012). 
 
In addition to the expression of IgA, a mixture of the prebiotics FOS and GOS enhanced 
delayed type hypersensitivity in an influenza vaccine model as a marker of T helper cell (Th1) 
immunity (Vos et al., 2006) and induced an immunoglobulin profile considered beneficial in 
infants at high risk for allergy (van Hoffen et al., 2009). FOS has also been demonstrated to 
increase circulating levels of IgM and IgG in plasma, suggesting that the influence of prebiotics 
is not limited to the gut (Janardhana et al., 2009). Furthermore, GOS has recently shown the 
ability to reduce the severity of colitis in mice through increasing the activity of natural killer 
(NK) cells in the spleen and mesenteric lymph nodes (MsLN) (Gopalakrishnan et al., 2012). 
GOS also stimulated NK expression of the chemokine receptor CCR9, which is involved in 
lymphocyte trafficking to the gut, pre-infection in the blood, spleen and MsLN (Gopalakrishnan 
et al., 2012). GOS mixture has also been reported to improve NK cell activity in highly active 
antiretroviral therapy (HAART)-naïve HIV-infected human individuals (Gori et al., 2011). In 
addition, prebiotics such as GOS could produce SCFA during fermentation (Lamsal, 2012), 







































FOS facilitated the proliferation of Lactobacilli, Bifidobacteria, both of which are involved in 
the induction of regulatory T cells (Treg), which play an important role in modulation of the 
immune system in C57BL/6J mice in response to Flu-vaccination (van't Land et al., 2010). FOS 
is also involved in the direct induction of Treg (van't Land et al., 2010). Therefore, FOS could 
modulate the chemotherapy-affected immune response through activation of suppressive T cell 
populations including Treg. To this end, bacteria, such as Bifidobacterium infantis 35624 
induced to proliferate by certain prebiotics, may enhance the activity of indoleamin 2,3-
dioxygenase which in turn may contribute to Treg production and T cell tolerance (Konieczna et 
al., 2012; Yasuda et al., 2012). 
 
In addition, β-1,4-mannobiose has been reported to exert prebiotic activity by stimulating both 
systemic and innate immune responses in the small intestine in one-day-old chicks (Ibuki et al., 
2010). MNB up-regulated the peptide transporter associated with antigen processing (TAP)-2 
expression (Ibuki et al., 2010), an essential factor for expression of the major histocompatibility 
complex (MHC) molecule on cell surfaces (Panter et al., 2012). Moreover, MNB up-regulated 
TNFSF15 gene expression in healthy chicks, related to the differentiation, proliferation and 
apoptosis of immune cells (Zhang and Li, 2012). Likewise, MNB enhanced healthy chick 
immunity through up-regulated expression of BLB-1, BF-2, IRF-1, IRF-7 and TLR3 genes 







































Furthermore, it has been shown that AXOS up-regulated the immune response in piglets by 
influencing the inflammatory and antibacterial protein pancreatitis associated protein (PAP) and 
down regulated Escherichia coli induced responses (Niewold et al., 2012). Interestingly, the 
higher degree of polymerization of AXOS seems to have a greater beneficial impact on health, as 
measured by enhanced phagocytic activity of fish macrophages as well as improved alternative 
haemolytic complement activity and total serum peroxidase content (Geraylou et al., 2012). As 
chemotherapy-induced mucositis is associated with a compromised immune system, prebiotics 
may have the potential to beneficially modify the immune response. 
 
Prebiotics and Inflammation 
The inflammatory process associated with mucositis is complex, and is characterised by a 
number of different mechanisms, including the production of pro-inflammatory cytokines, such 
as TNF-α, IL-6, IL-1β, nitric oxide (NO) and ROS (Abdelouhab et al., 2012; Liu et al., 2012). 
Administration of prebiotics such as inulin, FOS and germinated foodstuff have demonstrated 
efficacy in models of inflammatory intestinal disorders, including dextran sulphate sodium 
(DSS)-induced colitis, dimethylhydrazine-induced colon cancer, and chemotherapy (5-FU) 
induced rats mucositis (Araki et al., 2000; Kanauchi et al., 2003; Lara-Villoslada et al., 2006; 
Winkler et al., 2007; Smith et al., 2008; Abdelouhab et al., 2012).  
 
Initially, the beneficial effects demonstrated by prebiotics were believed to be due solely to 
their interaction with the commensal intestinal microbiota. However, recent indications suggest 






































oligofructose ingestion stimulated secretion of glucagon-like peptide-2 (Cani et al., 2009), a 
potent intestinal growth factor, in a rat model of DSS-induced colitis (Brubaker et al., 1997). 
Sung and Choi (2008) found that cyclooxygenase-2 expression in rats treated with 
dimethylhydrazine, was decreased following FOS administration, and it was proposed that this 
could represent a potential mechanism of action for certain prebiotics.  
 
Recently, inulin has been shown to significantly reduce colonic lesions in DSS-induced colitis 
in rats (Abdelouhab et al., 2012). Moreover, FOS ameliorated allergic peritoneal inflammation 
induced by ovalbumin (OVA), partially through the suppression of interleukin-5 (IL-5), and 
chemokine eotaxin in mice (Hosono et al., 2003; Yasuda et al., 2012). The IL-5 gene cluster and 
eotaxin are concomitant with the infiltration of eosinophils, neutrophils, mast cells and T 
lymphocytes into the airways of mice contributing to inflammation, particularly in Th2 type 
chronic inflammatory disease (Pilzner et al., 2012). Thus, it is likely that FOS influences cell 
populations such as T cells, basophils, mast cells, and epithelial cells (Hosono et al., 2003; 
Yasuda et al., 2012). 
 
GOS has demonstrated efficacy in inhibiting the adherence of pathogenic bacteria to Caco-2 
and HEp-2 cells in culture (Shoaf et al., 2006) and in vitro tests also demonstrated that GOS, in 
the absence of bacteria, stimulated sucrase activity in a Caco-2 cell line (Leforestier et al., 2009). 
More recently, it has been reported that the prebiotic, inulin has the ability to normalise increased 
NO levels, in peritoneal macrophage cultures from Swiss mice (Abdelouhab et al., 2012). In 






































via modification of Toll-like receptor (TLR) gene expression. Trevisi et al. (2008) found that 
FOS in combination with Bifidobacterium animalis increased expression of the TLR-2 encoding 
gene in the lymph nodes of piglets. The authors further described that TLR-2 and TLR-4 
encoding gene expressions were significantly associated with TNF-α encoding gene expression 
(Trevisi et al., 2008). On the other hand, Fukuda et al. (2011) revealed that germinated barley 
food stuff (containing prebiotics) decreased TLR-4 expression by increasing butyrate production 
and decreasing cyclooxygenase 2 mRNA expression in azoxymethane treated F344 rats. 
Furthermore, the consumption of XOS in combination with inulin decreased blood 
lipopolysaccharide (LPS) concentrations and attenuated LPS-induced increases in gene 
expression following IL-1β and LPS-induced decreases in gene expression of IL-13 in the blood 
of healthy humans (Lecerf et al., 2012). 
 
LPS can be recognized by TLR-4 with the MD-2, CD14 and LPS-binding protein (LBP). 
Initiation of this TLR signaling has also been involved in proteins of MyD88, Tirap, Trif, and 
Tram (Yamamoto et al., 2002; Yamamoto et al., 2003; Shigeoka et al., 2007). Ultimately, this 
LPS-TLR signaling leads to the induction or suppression of genes that orchestrate the 
inflammatory response through both MyD88 dependent and independent expression (Yamamoto 
et al., 2002; Yamamoto et al., 2003; Shigeoka et al., 2007). However, it is still not clear if 
prebiotics increase the immune response of intestinal epithelial cells by modifying TLR-4 in the 
MyD88 dependent, independent or other pathways. Future studies should focus on the effects of 
prebiotics on TLR-4 modification and its signaling pathways compared to LPS, as well as the 







































In a recent commentary, Howarth (2012) proposed that prebiotics have the potential to 
influence inflammasomes and modulate intestinal inflammation and function. Inflammasomes 
are a group of protein complexes built around several proteins including NLRP3, NLRC4, AIM2 
and NLRP6 (Strowig et al., 2012). These inflammasomes can recognize a wide range of 
microbial, stress and damage signals and following the activation of caspase-1, subsequently 
induce the secretion of pro-inflammatory cytokines such as IL-1 and IL-18 (Strowig et al., 2012). 
Inflammasomes can also induce pyroptosis, a form of cell death (Strowig et al., 2012). 
Furthermore, inflammasome-mediated processes play an important role in microbial infections, 
regulating metabolic processes, and mucosal immune responses in human diseases (Strowig et 
al., 2012). Indeed, a recent study by Qu et al. (2012) found that inflammasomes NLRC4 
phosphorylation (NLRC4 phospho-Ser 533) successfully inhibited the activation of caspase-1 
and pyroptosis in response to Salmonella typhimurium. This indicated that NLRC4 
phosphorylation could be a decisive point for NLRC4 inflammasome activation and host innate 
immunity (Qu et al., 2012). Future studies could investigate the potential for prebiotics to modify 
inflammasomes through different signaling pathways. This would further our understanding of 
prebiotics and their direct and indirect effects on inflammation in the chemotherapy-damaged 
intestine (Howarth, 2012). 
 
The influence of prebiotics on inflammation in mucositis requires further investigation. Future 
studies should not only focus on histological or inflammatory cytokine related responses, but 






































The journey to identify the key genes related to chemotherapy-induced inflammation, and 
whether prebiotics could control or alter this inflammation at the gene or protein level, promises 
to be an exciting and worthwhile focus for the future. 
 
Prebiotics and Synbiotics as Potential Treatment Strategies for Mucositis 
To date, there have been few rigorous scientific investigations into the interactions of 
prebiotics in the healthy and diseased small intestine. In particular, the area of intestinal 
mucositis remains largely unexplored, with only one published study investigating FOS in a rat 
model of 5-Fluorouracil (5-FU) induced mucositis (Smith et al., 2008). This study demonstrated 
that FOS was able to marginally reduce myeloperoxidase activity, an indicator of neutrophil 
infiltration, in the proximal small intestine of chemotherapy-treated rats. However, no other 
beneficial effects were evident in the other parameters measured. Similarly, there is only a single 
report of a synbiotic investigation in mucositis, whereby FOS and the new probiotic 
Lactobacillus fermentum BR11, was administered to rats (Smith et al., 2008). Nevertheless, their 
combination did not seem to exert a further improvement in the severity of mucositis than 
administered L. fermentum BR11 to rats alone (Smith et al., 2008). More recently, the 
combination of GOS and Bifidobacterium strain (B. longum subsp. longum PCB133) 
significantly inhibited pathogenic Campylobacter jejuni levels, a pathogen responsible for food-
borne gastroenteritis in humans (Baffoni et al., 2012). Considered together, investigations of 
prebiotics and synbiotics provide a fertile area for further research in disorders of the small 







































When used in combination, prebiotics and probiotics may complement each other to achieve a 
synergistic or additive effect in an attempt to ameliorate mucositis (Geraylou et al., 2012). 
 
Probiotics have been studied extensively in relation to gut health (Parnell and Reimer, 2012; 
Shimizu et al., 2012). However, only recently have prebiotics been examined specifically in 
relation to chemotherapy-induced mucositis (Smith et al., 2008). Although it remains unknown 
whether they can be considered as new agents for the treatment of chemotherapy-induced 
mucositis, prebiotics and synbiotics require investigation in relation to factors such as 
composition, dose, molecular mechanisms and gene expression, both in vitro and in vivo, 
specifically as they relate to the different mechanisms underlying mucositis pathogenesis. 
 
In conclusion, prebiotics are demonstrating efficacy as growth promoters, anti-inflammatory 
agents and microbial modulators making them promising candidates for the potential treatment 
of chemotherapy-induced mucositis. The challenge for the future will be the development of 
predictive in vitro, animal model and clinical trial systems to specifically identify the most 
efficacious probiotics, prebiotics and synbiotic combinations for this debilitating condition.  
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